J&J agrees to pay $2.2 billion upfront for Ollin and its retinal disease antibody
Johnson & Johnson will buy the eye disease biotech for $2.2 billion upfront plus up to about $1.125 billion in milestones, and Blackstone has agreed to pay $750 million toward the Phase 3 program for OLN324.

- Value
- $2.2B
- Type
- Acquisition
- Target
- Ollin Biosciences
- Buyer
- Johnson & Johnson
- Sector
- Biotech
- Announced
- Nov. 16, 2026
Johnson & Johnson is paying $2.2 billion upfront for a biotech founded three years ago, and it has lined up an outside investor to pay for the late-stage trials.
J&J said Nov. 16 that it signed a definitive agreement to acquire Ollin Biosciences, a clinical-stage company working on serious eye diseases. Ollin's shareholders could receive up to about $1.125 billion more in regulatory and commercial milestone payments, bringing the potential total to about $3.3 billion, according to J&J's announcement and CNBC.
Why it matters: The deal pairs a big-pharma acquisition with private money for the late-stage trials, so an outside investor rather than J&J is set to pay for the Phase 3 program. Blackstone Life Sciences agreed to pay J&J a total of $750 million over several years to fully fund Phase 3 development of Ollin's lead drug, contingent on the acquisition closing.
The drug
Ollin's lead candidate, OLN324, is an investigational bispecific antibody that targets two pathways involved in retinal disease, VEGF and Ang2, according to J&J. The company describes it as a next-generation antibody with high Ang2 potency in a small format it calls a minibody. It is being developed for wet age-related macular degeneration and diabetic macular edema, two conditions that J&J said affect more than 40 million people worldwide.
J&J described OLN324 as a Phase 3 investigational antibody. CNBC reported that Ollin plans to begin late-stage studies in the second half of 2026. A second Ollin program, OLN102, is in preclinical development for thyroid eye disease and Graves' disease, CNBC reported.
"OLN324 selectively targets two important drivers of retinal disease," said Kip Connor, J&J's vice president and ophthalmology disease area stronghold leader.
Who is selling
Ollin is a Texas company established in 2023 and backed by ARCH Venture Partners and Mubadala Capital, CNBC reported. It raised $330 million in June to fund its trials, according to the outlet. Neither J&J's release nor CNBC disclosed how much Ollin had raised in total.
For J&J, the acquisition builds on what the company called its long-standing presence in vision. CNBC noted that J&J has a large contact lens business but a limited footprint in drugs for eye disease.
The Blackstone piece
In return for its $750 million, Blackstone will be eligible for certain regulatory and sales milestone payments plus single-digit royalties, J&J said. CNBC pointed to another recent Blackstone commitment: the previous week, Pfizer said Blackstone would provide up to $1.5 billion through 2028 for an experimental monthly obesity treatment.
What comes next
J&J expects the acquisition to close before the end of 2026, subject to regulatory approvals and customary closing conditions. It said it will disclose how it will account for the deal on or before closing. The release did not say how J&J will fund the upfront payment or when the first Phase 3 trial will enroll patients.



